Meloxicam

Abstract
▴ Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis ▴ It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the constitutive form of this enzyme (COX-1), inhibition of which is associated with gastric, renal and other adverse effects ▴ It has anti-inflammatory effects similar to or better than those of other NS AIDs in animal models, and a greater therapeutic ratio (ulcerogenic potential: efficacy in adjuvant arthritis) ▴ In healthy volunteers meloxicam 7.5 or 15mg caused less gastrointestinal mucosal damage on endoscopy than piroxicam 20mg, with a significant difference between meloxicam 7.5mg and piroxicam ▴ In comparative clinical trials, meloxicam was at least as effective as piroxicam and naproxen in patients with rheumatoid arthritis, and diclofenac and piroxicam in patients with osteoarthritis ▴ Meloxicam was at least as well tolerated as piroxicam, diclofenac or naproxen overall but had improved gastrointestinal tolerability compared with these agents.

This publication has 24 references indexed in Scilit: